VIATRIS INC. (VTRS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $12.60M; Additional Paid in CapitalUSD $18.56B; Treasury Stock, ValueUSD $1.16B; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD (m).
- 2026-03-31: Common Stock, Value, IssuedUSD $12.60M; Additional Paid in CapitalUSD $18.66B; Treasury Stock, ValueUSD $1.01B; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD (m).
- 2025-12-31: Common Stock, Value, IssuedUSD $12.50M; Additional Paid in CapitalUSD $18.80B; Treasury Stock, ValueUSD $1.01B; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD (m).
- 2025-09-30: Common Stock, Value, IssuedUSD $12.50M; Additional Paid in CapitalUSD $18.89B; Treasury Stock, ValueUSD $924.20M; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD (m).
VIATRIS INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings USD | Adjustments to Additional Paid in Capital, Other USD | Treasury Stock, Shares, Acquired shares | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Retired, Cost Method, Amount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.60M | $18.56B | $1.16B | (m) | (m) | (m) | $-2.82B | $-330.70M | $14.26B | 103.55M | 3 month · $150.00M | 3 month · $38.70M 6 month · $86.90M | 3 month · $142.60M 6 month · $288.40M | (m) | 3 month · 9.40M | (m) | (m) |
| 2026-03-31 | $12.60M | $18.66B | $1.01B | (m) | (m) | (m) | $-2.80B | $-211.90M | $14.66B | 94.18M | (m) | 3 month · $48.20M | 3 month · $145.80M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $12.50M | $18.80B | $1.01B | (m) | (m) | (m) | $-2.71B | $-388.30M | $14.71B | 94.18M | 12 month · $502.90M | 12 month · $177.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $12.50M | $18.89B | $924.20M | (m) | (m) | (m) | $-2.71B | $-48.20M | $15.22B | 86.12M | 3 month · $68.40M 9 month · $419.90M | 3 month · $36.00M 9 month · $128.30M | 3 month · $143.60M | (m) | 3 month · 6.80M 9 month · 45.60M | (m) | (m) |
| 2025-06-30 | $12.50M | $19.00B | $855.80M | (m) | (m) | (m) | $-2.66B | $80.00M | $15.57B | 79.33M | 3 month · $176.00M 6 month · $351.50M | 3 month · $37.10M 6 month · $92.30M | (m) | (m) | 3 month · 20.20M 6 month · 38.90M | (m) | (m) |
| 2025-03-31 | $12.40M | $18.96B | $679.80M | (m) | (m) | (m) | $-2.87B | $227.90M | $15.65B | 59.09M | 3 month · $175.50M | 3 month · $55.20M | (m) | (m) | 3 month · 18.60M | (m) | (m) |
| 2024-12-31 | $12.30M | $18.92B | $504.30M | $-3.99B | $-1.20M | $-254.20M | $-3.21B | $3.42B | $18.64B | 40.48M | 12 month · $252.50M | 12 month · $146.10M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $12.30M | $18.89B | $504.30M | $-3.17B | $-600.00K | $262.50M | $-2.69B | $4.08B | $19.79B | 40.48M | 9 month · $252.50M | 3 month · $32.40M 9 month · $113.80M | (m) | (m) | 9 month · 19.20M | (m) | (m) |
| 2024-06-30 | $12.30M | $18.85B | $504.30M | $-3.68B | $-1.40M | $-261.70M | $-2.98B | $4.13B | $19.52B | 40.48M | 6 month · $252.50M | 3 month · $34.70M 6 month · $81.40M | (m) | (m) | 6 month · 19.20M | (m) | (m) |
| 2024-03-31 | $12.30M | $18.84B | $504.30M | $-3.59B | $-1.40M | $-266.40M | $-2.94B | $4.61B | $20.01B | 40.48M | 3 month · $252.50M | 3 month · $46.70M | (m) | (m) | 3 month · 19.20M | (m) | (m) |
| 2023-12-31 | $12.20M | $18.81B | $251.80M | $-3.25B | $-1.20M | $-271.40M | $-2.75B | $4.64B | $20.47B | 21.24M | 12 month · $251.80M | 12 month · $180.70M | (m) | 12 month · $6.10M | (m) | (m) | (m) |
| 2023-09-30 | $12.20M | $18.76B | $251.80M | $-3.95B | $-2.50M | $260.50M | $-3.21B | $5.55B | $20.87B | 21.24M | 9 month · $251.80M | 3 month · $43.10M 9 month · $124.90M | (m) | 9 month · $6.10M | 9 month · 21.20M | (m) | (m) |
| 2023-06-30 | $12.20M | $18.72B | $251.80M | $-3.59B | $-1.30M | $-264.50M | $-3.01B | $5.37B | $20.84B | 21.24M | 6 month · $251.80M | 3 month · $39.20M 6 month · $81.80M | (m) | 6 month · $6.10M | 6 month · 21.20M | (m) | (m) |
| 2023-03-31 | $12.20M | $18.68B | $251.80M | $-3.34B | $-1.60M | $-269.30M | $-2.76B | $5.25B | $20.93B | 21.24M | 3 month · $251.80M | 3 month · $42.60M | (m) | 3 month · $6.10M | 3 month · 21.20M | (m) | (m) |
| 2022-12-31 | $12.10M | $18.65B | $0.00 | $-3.39B | $-2.30M | $-268.50M | $-2.76B | $5.18B | $21.07B | 0.00 | (m) | 12 month · $116.40M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $12.10M | $18.62B | $0.00 | $-4.58B | $-2.70M | $29.20M | $-3.76B | $4.31B | $19.18B | 0.00 | (m) | 3 month · $29.10M 9 month · $86.80M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $12.10M | $18.59B | $0.00 | $-3.42B | $-2.10M | $-30.10M | $-2.90B | $4.11B | $19.81B | 0.00 | (m) | 3 month · $29.40M 6 month · $57.70M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $12.10M | $18.56B | $0.00 | $-2.27B | $-1.30M | $-29.40M | $-2.06B | $3.94B | $20.45B | 0.00 | (m) | 3 month · $28.30M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $12.10M | $18.54B | $0.00 | $-1.80B | $0.00 | $-32.20M | $-1.74B | $3.69B | $20.49B | 0.00 | (m) | 12 month · $111.20M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $12.10M | $18.51B | (m) | $-1.43B | $300.00K | $44.90M | $-1.47B | $4.09B | $21.14B | (m) | (m) | 3 month · $25.00M 9 month · $88.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $12.10M | $18.49B | (m) | $-1.02B | $400.00K | $-43.60M | $-1.21B | $3.91B | $21.21B | (m) | (m) | 3 month · $31.00M 6 month · $63.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $12.10M | $18.46B | (m) | $-1.18B | $200.00K | $26.30M | $-1.39B | $4.32B | $21.41B | (m) | (m) | 3 month · $32.70M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $12.10M | $18.44B | $0.00 | $-461.50M | $1.20M | $26.10M | $-858.00M | $5.36B | $22.95B | (m) | (m) | 12 month · $79.20M | (m) | (m) | (m) | (m) | 12 month · $0.00 |
| 2020-09-30 | (m) | (m) | (m) | $-1.19B | $1.40M | $-14.50M | $-1.42B | (m) | $12.55B | (m) | (m) | 3 month · $15.10M 9 month · $49.80M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-27 | $0.00 | $-31.00M | (m) | (m) | (m) | (m) | $0.00 | $-170.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-201.00M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $-1.88B | $1.30M | $12.40M | $-2.02B | (m) | $11.75B | (m) | (m) | 3 month · $15.30M 6 month · $34.70M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-28 | $0.00 | $-300.00K | (m) | (m) | (m) | (m) | $0.00 | $-900.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-1.00M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $-2.33B | $800.00K | $19.00M | $-2.45B | (m) | $11.26B | (m) | (m) | 3 month · $19.40M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-29 | $1.00 | $0.00 | (m) | (m) | (m) | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2019-12-31 | $6.10M | $8.64B | $999.70M | $-1.67B | $600.00K | $17.40M | $-1.80B | $6.03B | $11.88B | (m) | 12 month · $0.00 | 12 month · $56.80M | (m) | (m) | (m) | $0.00 | (m) |
| 2019-09-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2019-03-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2019-02-13 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $12.17B | (m) | 12 month · $432.00M | 12 month · $-3.30M | (m) | (m) | 12 month · 9.80M | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $13.31B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |